Background: Myelodysplastic syndromes (MDSs) are a heterogeneous group of bone marrow disorders. Morphology may be difficult to evaluate in some patients, either due to hypocellularity or fibrosis of bone marrow. Objective: To define immunophenotypic pattern in MDS patients, quantify and score complex flow cytometric abnormalities, and to correlate flow cytometry scores with conventional and established parameters used in MDS diagnosis. Methods: Using flow cytometry, we studied 40 bone marrow specimens 30 patients with MDS and 10 cytopenic patients with non-clonal hematologic disorders as control group. A panel of monoclonal antibodies including: CD45, CD13, CD33, CD34, CD7, CD11b, CD16, CD56 and HLA-DR were used. Immunophenotyping using 2 gates were done: Forward (FSC) and right angle light scatter SSC and a second gate were done on the basis of CD45 staining and SSC to confirm identification of the selected cells. These combinations of Moab were used to measure the degree of maturation of their corresponding antigen by expressing their intensity. Results: For MDS diagnosis, FCM had a sensitivity and specificity of 86.7% and 80% with score 1.5:9, 80% and 100% with score 3.5:9, 53.3% and 100% with score 5:9 and 30% and 100% with score 6.5:9 respectively, and a significant positive correlation between IPSS and FCM score. Conclusion: This study defines immunophenotypic pattern in MDS patients and allow for a simple numerical display of results as score which is positively correlated with IPSS.
INTRODUCTION
yelodysplastic syndrome (MDS) is a premalignant, clonal, haematopoietic stem cell disorder that features refractory cytopenia, ineffective hematopoiesis, dysplastic hematopoietic cell differentiation in multiple lineages of hematopoietic cells, and increased risk of progression to acute myeloid leukemia (1) . The diagnosis and management of patients with (MDSs) remain challenges that are distinct from those for most other hematologic malignancies. Therapeutic goals vary among individuals and are influenced by hematologic features, prognosis, and age. No single treatment is uniformly effective or addresses the clinical needs of all patients .The standard of care ranges from amelioration of hematologic deficit with blood product transfusions and administration of recombinant growth factors to aggressive chemotherapy and stem cell transplantation for younger individuals with more aggressive disease (2) . The aim of this work is to define immunophenotypic patterns in MDS patients and quantify and score complex flow cytometric abnormalities, then correlate flow cytometry scores with conventional and established parameters used in MDS diagnosis.
MATERIALS AND METHODS This study comprised 30 patients who were diagnosed as MDS selected from Clinical Pathology Department and Medical Oncology Unit, Internal Medicine Departments, Zagazig University Hospitals and The diagnosis of MDS was established based on WHO (World Health Organization) classification and derived from combined clinical, morphologic, and cytogenetic data. , and ten bone marrow specimens were got from patients who admit to the hospital for ITP and/or hypersplenism diagnosis.
Investigations:
Full history taking and clinical examination: particularly for pallor, purpuric eruption, hepatomegaly, spleno-megaly and lymphadenopathy. Routine investigations were done for all studied subjects; Abdominal and pelvis ultra-sonography, Liver function tests, kidney function tests, uric acid and LDH using ADVIA 1650 (Bayer), Complete blood picture using Sysmex Kx 21(Roche) and examination of bone marrow aspirates (Leishman stain). Cytogenetic analysis were done for patient`s group only. MDS patients were scored according to IPSS score. IPSS score is calculated based on marrow blast percentage, karyotype, and the number of cytopenias according to IPSS score.
Immunophenotyping was done using a panel of monoclonal antibodies labeled with FITC and PE including: CD45 ,CD13, CD33, CD34 CD7, CD11b , CD16, CD56 and HLADR using FACSCan flow cytometry (Becton Dickinson San Jose, CA). All mono-clonal antibodies used were purchased from Dako (Denmark), and the cut off for positivity for all was set at 20%. These investigations were approved by the local Ethics Committees. Both myeloid cells and monocytes showed 2 or 3 abnormalities. 4
METHODS
One additional point was given if myeloblasts were less than 5% but clearly abnormal. Two additional points were given for 5% to 10% abnormal myeloblasts, 3 points for 11% to 20%, and 4 points for 21% to 30% (there were no patients with more than 5% myeloblasts that had phenotypically normal myeloblasts). Total scores reflecting the degree of flow cytometric aberrancies were grouped into the following categories: 0-1 normal/mild ; 2-3 moderate ; 4-9 sever.
Statistical analysis:
Data analysis was done using the computer software statistical package for social sciences (SPSS) version 17.0. Fisher exact (x 2) test was used for categorical variables. Pearson's correlation coefficient (r) was used to test the correlation between continuous variables. P-value 0.05 was considered significant and 0.001 was considered highly significant.
Results
There was a significant statistical difference between the two groups as regards karyotyping (P<0.05) (table1)
The number and percentage of patients with 5q-, RA, RAEB I and RAEB II were 1 (3.3%), 12 (40%), 7 (23.3%) and 10 33.3% respectively (table 2).
There was a significant positive correlations between IPSS score and karyotying (r =0.853, P = 0.000), LDH(r =0.690, P = 0.000) and BM blast (r =0.824, P = 0.000) and significant negative correlations between IPSS score and TLC (r=-0.376, P= 0.04), and PLT (r = -0.636, P = 0.000), No correlation between FCM score with the same parameters (table 3) . Highly significant positive correlations between FCM score and IPSS score (r =0. 0.582, P = 0.001), presence of lymphatic markers on granulocytes (r =0.433, P = 0.017), CD11b (r =0.682, P = 0.000), presence of lymphatic markers on monocytes (r =0.585, P = 0.001),number of FCM abnormalities on granulocytes (r=0.371, P = 0.043), Number of FCM abnormalities on monocytes (r=0.548, P = 0.002) (table 4) . FCM score had sensitivity and specificity of (86.7%, 80%) in score 1.5: 9, (80%, 100%) in score 3.5: 9, (53.3%, 100%) in score 5: 9 and (30%, 100%) in score 6.5: 9 (table 5) . The objective of the present study was to define immunophenotypic pattern in MDS patients and quantify and score complex flow cytometric abnormalities, then correlate flow cytometry scores with conventional and established parameters used in MDS diagnosis. This study was carried out on 30 patients with a diagnosis of MDS entering oncology department (confirmed at our laboratory), and 10 healthy subjects as a control. MDS subgroups in this study were divided into 5q-was (3.3%) ,RA was (40%) ,RAEB I (23.3%) and RAEB II was ( 33.3%) ,meanwhile Xu et al., (2013) (3) found RA(14.2%),RCM(42%),RCEBI (28.2%),RAEBII(14%),MDS-U(1.7%),5q-(0%). A significant positive correlation in group II between IPSS score and karyotying ( P = 0.000), LDH ( P = 0.000) and BM blast ( P = 0.000) and significant negative correlation between IPSS score and TLC( P = 0.04) , and PLT( P = 0.000) as these parameters were included in IPSS score
.No correlation between IPSS and ANC, Hb, CD45, CD13/CD16, CD56, HLADR, CD34,presence of lymphatic marker on granulocyte and on monocytes, CD7, CD11b In MDS group we found significant positive correlation between FCM score and IPSS score ( P = 0.001),
Presence of lymphatic markers on granulocytes( P = 0.017) , CD11b ( P = 0.000) , Presence of lymphatic markers on monocytes ( P = 0.001),number of FCM abnormalities on granulocytes( P = 0.043) , number of FCM abnormalities on monocytes ( P = 0.002 (5) reported that FCM score and advanced scoring showed significant correlation with cytogenetic prognosis (Spearman r= 0.379,P,0.001) , but early scoring had an inverse correlation with cytogenetic prognosis (Spearmanr =20.213,P= 0.004) Therefore, FCM scores divided into early scoring and advanced scoring could contribute to disease classification, stage evaluation and treatment options for MDS. So this disagreement with our results may be explained with smaller number of cases in our study and may be due to we did not divide the FCM score to early and advanced score.
Xu et al.,(2013)
(3) agree with our results, found no correlation between FCM score and peripheral cytopenias(-0.076, P=0.455). Our FCM score had sensitivity and specificity of ( 86.7% ,80%) in score 1.5 : 9 , (80% ,100% ) in score 3.5 : 9 ,(53.3 %,100%) in score 5 : 9 and (30%,100% ) in score 6.5: 9.This result was close to the results of Della Porta (2012) ( designed a FCMSS to diagnose low-grade MDS based on immunophenotyping in CD34+ cells, which showed 58% of sensitivity and 100% of specificity. The inter-laboratory bias may have negative effect on the diagnostic power. It is still difficult to construct standardized FCM detection assay in different labs. The RECOMMENDATIONS  Further studies should be done to refine the FCSS by incorporating additional antibodies; the methodology must remain practical if it is to be applied routinely.
 efforts should be directed at expanding our abilities to phenotypically chara-cterize the erythroid compartment  More studies on large numbers of patients are needed to confirm these results. CONCLUSION Our scoring system tested the components of myeloid maturation separately monocytes, and neutrophils . The phenotypic abnormalities on the maturing myeloid and monocytoid are abnormalities detected in MDS patients were different from individual to individual prompting a scoring system based on the sum of the abnormalities rather than focusing on individual antigenic differences.
biological signals of abnormal maturation. Based on the abnormal pattern, we developed and validated a convenient and economical FCM score diagnostic system with good sensitivity and specificity to assist the diagnosis of MDS
